Akkermansia muciniphila and Gut Immune System: A Good Friendship That Attenuates Inflammatory Bowel Disease, Obesity, and Diabetes

Rodrigues, Vanessa Fernandes; Elias-Oliveira, Jefferson; Pereira, Ítalo Sousa; Pereira, Jéssica Assis; Barbosa, Sara Cândida; Machado, Melissa Santana Gonsalez; Carlos, Daniela

doi:10.3389/fimmu.2022.934695

Cited by 128 publications

(96 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly however, pasteurized A. muciniphila , live A. muciniphila , and even secreted proteins (e.g., Amuc_1100) and extracellular vesicles can regulate gut barrier function and/or the immune system by acting on different molecules. Regarding the effects of A. muciniphila on human health (e.g., “microbiota metabolites,” “immune system,” and “gut barrier function”), interested readers may wish to refer to previous detailed explorations of such topics ( Yan et al, 2021 ; Rodrigues et al, 2022 ). The molecular mechanisms underlying these effects are an ongoing hot topic in the field.…”

Section: Discussionmentioning

confidence: 99%

Global trends in Akkermansia muciniphila research: A bibliometric visualization

Wang

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

BackgroundAkkermansia muciniphila is a member of the gut microbiome, using mucin as sources of carbon, nitrogen, and energy. Since the first discovery of this unique bacterium in 2004, A. muciniphila has been extensively studied. It is considered a promising “next-generation beneficial microbe.” The purpose of this paper is to sort out the research status and summarize the hotspots through bibliometric analysis of the publications of A. muciniphila.MethodsThe publications about A. muciniphila from January 2004 to February 2022 were obtained from the Web of Science Core Collection. Visualization analyses were performed using three bibliometric tools and GraphPad Prism.ResultsA total of 1,478 published documents were analyzed. Annual publication number grew from 1 in 2004 to 336 in 2021, with China being the leading producer (33.36%). De Vos, Willem M was the most productive author with the highest H-index (documents = 56, H-index = 37), followed by Cani, Patrice D (documents = 35, H-index = 25). And Scientific Reports published the most papers. PNAS was the keystone taxa in this field, with high betweenness centrality (0.11) and high frequency. The keywords with high frequency in recent years include: oxidative stress, diet, metformin, fecal microbiota transplantation, short-chain fatty acids, polyphenols, microbiota metabolites and so on. The keyword “oxidative stress” was observed to be increasing in frequency recently.ConclusionOver time, the scope of the research on the clinical uses of A. muciniphila has gradually increased, and was gradually deepened and developed toward a more precise level. A. muciniphila is likely to remain a research hotspot in the foreseeable future and may contribute to human health.

show abstract

Section: Discussionmentioning

confidence: 99%

Global trends in Akkermansia muciniphila research: A bibliometric visualization

Wang

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Akkermansia , a genus of the phylum Verrucomicrobia , is also known as a beneficial gut microbe because of its advantage in the maintenance of gut integrity ( Taherali et al, 2018 ; Cani et al, 2022 ). A. muciniphila slows down the development and progression of diabetes, obesity, and IBD in mice ( Rodrigues et al, 2022 ), which was enriched by the total flavones of Abelmoschus manihot treatment in CRF rat models ( Tu et al, 2020 ).…”

Section: Animal Studies Of Natural Products For the Treatment Of Ckd ...mentioning

confidence: 99%

Natural products from plants and microorganisms: Novel therapeutics for chronic kidney disease via gut microbiota regulation

et al. 2023

View full text Add to dashboard Cite

Dysbiosis of gut microbiota plays a fundamental role in the pathogenesis and development of chronic kidney disease (CKD) and its complications. Natural products from plants and microorganisms can achieve recognizable improvement in renal function and serve as an alternative treatment for chronic kidney disease patients with a long history, yet less is known on its beneficial effects on kidney injury by targeting the intestinal microbiota. In this review, we summarize studies on the effects of natural products from plants and microorganisms, including herbal medicines and their bioactive extracts, polysaccharides from plants and microorganisms, and phytochemicals, on the prevention and treatment of chronic kidney disease through targeting gut microflora. We describe the strategies of these anti-CKD effects in animal experiments including remodulation of gut microbiota structure, reduction of uremic toxins, enhancement of short-chain fatty acid (SCFA) production, regulation of intestinal inflammatory signaling, and improvement in intestinal integrity. Meanwhile, the clinical trials of different natural products in chronic kidney disease clinical practice were also analyzed and discussed. These provide information to enable a better understanding of the renoprotective effects of these effective natural products from plants and microorganisms in the treatment of chronic kidney disease. Finally, we propose the steps to prove the causal role of the intestinal microflora in the treatment of chronic kidney disease by natural products from plants and microorganisms. We also assess the future perspective that natural active products from plants and microorganisms can beneficially delay the onset and progression of kidney disease by targeting the gut flora and highlight the remaining challenges in this area. With the continuous deepening of studies in recent years, it has been proved that gut microbiota is a potential target of natural active products derived from plants and microorganisms for chronic kidney disease treatment. Fully understanding the functions and mechanisms of gut microbiota in these natural active products from plants and microorganisms is conducive to their application as an alternative therapeutic in the treatment of chronic kidney disease.

show abstract

“…As a beneficial paradigm, Akkermansia muciniphila, a species of human commensal bacterium with mucin-degrading capability that abundantly resides in the mucus layer, can counteract inflammation-associated insulin resistance, display favorable metabolic effects on host glucose and adipose metabolism, reinforce intestinal barrier function, and influence host immune responses. Indeed A. muciniphila has shown therapeutic potentials in several inflammation-related diseases, including inflammatory bowel disease (IBD) and diabetes (30)(31)(32). In autoimmune diseases characterized by the overactivation of immune cells and aberrant self-attack (33), how glycosylation links glucose metabolism to the multiple physiopathological changes in the immune system and gut ecosystem is of great interest.…”

Section: Introductionmentioning

confidence: 99%

Glucose metabolism and glycosylation link the gut microbiota to autoimmune diseases

Wang

Yang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Carbohydrates serve as important energy sources and structural substances for human body as well as for gut microbes. As evidenced by the advances in immunometabolism, glucose metabolism and adenosine triphosphate (ATP) generation are deeply involved in immune cell activation, proliferation, and signaling transduction as well as trafficking and effector functions, thus contributing to immune response programming and assisting in host adaption to microenvironment changes. Increased glucose uptake, aberrant expression of glucose transporter 1 (e.g., GLU1), and abnormal glycosylation patterns have been identified in autoimmunity and are suggested as partially responsible for the dysregulated immune response and the modification of gut microbiome composition in the autoimmune pathogenesis. The interaction between gut microbiota and host carbohydrate metabolism is complex and bidirectional. Their impact on host immune homeostasis and the development of autoimmune diseases remains to be elucidated. This review summarized the current knowledge on the crosstalk of glucose metabolism and glycosylation in the host with intestinal microbiota and discussed their possible role in the development and progression of autoimmune diseases. Potential therapeutic strategies targeting glucose metabolism and glycosylation in modulating gut ecosystem and treating autoimmune diseases were discussed as well.

show abstract

Akkermansia muciniphila and Gut Immune System: A Good Friendship That Attenuates Inflammatory Bowel Disease, Obesity, and Diabetes

Cited by 128 publications

References 88 publications

Global trends in Akkermansia muciniphila research: A bibliometric visualization

Global trends in Akkermansia muciniphila research: A bibliometric visualization

Natural products from plants and microorganisms: Novel therapeutics for chronic kidney disease via gut microbiota regulation

Glucose metabolism and glycosylation link the gut microbiota to autoimmune diseases

Contact Info

Product

Resources

About